RemeGen Co

RemeGen Co Net Debt/FCF

The Net Debt to Free Cash Flow Ratio of RemeGen Co (688331.SS) as of Oct 26, 2026 is 6.63. In the previous year, Net Debt to Free Cash Flow Ratio was -1.33 — a change of -599.72% (higher).

Net Debt/FCF

6.63

YoY

-599.72%

Last updated:

Net Debt to Free Cash Flow Ratio of RemeGen Co is 2025 6.63 . Net Debt to Free Cash Flow Ratio of RemeGen Co was 2024 -1.33 . It decreases by -599.72% higher compared to the previous year.

The RemeGen Co Net Debt/FCF history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Net Debt/FCF
Date
Net Debt/FCF
Jan 1, 2018
-4.05 CNY
Jan 1, 2019
-1.77 CNY
Jan 1, 2020
2.25 CNY
Jan 1, 2021
4.68 CNY
Jan 1, 2022
0.94 CNY
Jan 1, 2023
-0.23 CNY
Jan 1, 2024
-1.33 CNY
Jan 1, 2025
6.63 CNY
The RemeGen Co Net Debt/FCF history
YEARNet Debt/FCFYoY
6.63-599.72%
-1.33+466.73%
-0.23-124.84%
0.94-79.85%
4.68+107.53%
2.25-227.29%
-1.77-56.25%
-4.05—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

RemeGen Co Stock analysis

What does RemeGen Co do? RemeGen Co Ltd generates revenue by researching, developing, and manufacturing innovative biopharmaceuticals, specifically focusing on therapeutic antibody drugs. The company's product portfolio includes tetacept (RC18), veldicitumab (RC48), and a dual-target fusion protein (RC28). These products are designed to treat major diseases such as oncology, autoimmune diseases, and ophthalmology. The firm operates primarily in the domestic market within China, where it commercializes its discoveries. Its business model relies on the development of various antibody types, including antibody drug conjugates (ADCs), antibody fusion proteins, monoclonal antibodies, and bispecific antibodies. This focus allows the company to address significant medical needs through its specialized therapeutic offerings. RemeGen Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about RemeGen Co stock

Net Debt to Free Cash Flow Ratio of RemeGen Co is 6.63 in 2025.

Net Debt to Free Cash Flow Ratio of RemeGen Co changed from -1.33 to 6.63, representing a -599.72% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Net Debt to Free Cash Flow Ratio RemeGen Co since 2006 – with annual values, charts, and detailed analysis.

Net Debt/FCF indicates how many years it would take to repay net debt using free cash flow. Lower ratios suggest faster deleveraging potential.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Net Debt to Free Cash Flow Ratio's RemeGen Co with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Leverage — RemeGen Co

All Key Metrics — RemeGen Co